Risk of Increased Respiratory Adverse Reactions
ARIKAYCE has been associated with a risk of increased respiratory adverse reactions, including, hypersensitivity pneumonitis, hemoptysis, bronchospasm, and exacerbation of underlying pulmonary disease that have led to hospitalizations in some cases.
Patient counseling
Medical guidelines
Package inserts
Additional information
Keywords: Arikayce
Updated: October 2018
Disclaimer: This information presents a SUMMARY of Black Box data from product information labeling and does not address additional warnings, precautions, or other important safety data in the product insert. Patient care decisions SHOULD NOT be made without reviewing the most recent product information insert, which may be obtained from the manufacturer. This table may not be complete as it was prepared using product information from package inserts. It is periodically updated with supplemental information from FDA safety alerts, the FDA labeling announcements, and new drug approvals.
Formweb is a product of Rpharmy, LLC.
Visit our website at rpharmy.com for more information on online formularies featuring Black Box Warnings.